Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.25 | — | — | — | — | 0.68 | — | — | — | — | — | — | 2.24 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9999.00 | 45.30 | 38.68 | 48.23 | 43.76 | 72.41 | 71.08 | 50.33 | 43.81 | 46.67 | 58.65 | 56.58 | 89.24 |
| — | -37.4% | -45.6% | -4.2% | -0.1% | +55.2% | +21.2% | -11.0% | -50.9% | -57.7% | +7.8% | -88.1% | — | |
| P/B Ratio | 1.47 | 1.82 | 1.41 | 1.15 | 1.22 | 1.60 | 3.71 | 2.22 | 1.53 | 1.56 | 1.63 | 1.22 | 1.40 |
| — | +13.9% | -62.1% | -48.2% | -20.6% | +2.5% | +127.1% | +81.0% | +9.8% | +5.4% | +51.1% | -6.9% | +1.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | 10.16 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Agios Pharmaceuticals, Inc.'s operating margin was -907.4% in Q3 2025, up 112.8 pp QoQ and up 239.6 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -1078.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 4.7% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.3% | 87.0% | 76.2% | 87.6% | 88.3% | 91.3% | 64.2% | 75.9% | 72.0% | 91.4% | 17.0% | 11.7% | -11.1% |
| — | -4.7% | +18.8% | +15.4% | +22.6% | -0.2% | +277.1% | +547.8% | +746.5% | +315.1% | +154.6% | +102.2% | — | |
| Operating Margin | -873.9% | -907.4% | -1020.1% | -1222.0% | -1165.3% | -1146.9% | -1228.3% | -1124.3% | -1496.2% | -1363.7% | -1396.0% | -1615.5% | -2301.0% |
| — | +20.9% | +16.9% | -8.7% | +22.1% | +15.9% | +12.0% | +30.4% | +35.0% | +47.4% | +20.2% | +86.7% | — | |
| Net Margin | -764.0% | -803.1% | -899.4% | -1023.3% | -899.6% | 10574.7% | -1115.7% | -995.8% | -1350.7% | -1234.3% | -1248.6% | -1444.4% | 847.5% |
| — | -107.6% | +19.4% | -2.8% | +33.4% | +956.8% | +10.6% | +31.1% | -259.4% | +46.9% | +24.1% | +87.3% | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -7.8% | -7.9% | -5.9% | -6.1% | 82.9% | -13.7% | -10.5% | -11.3% | -9.9% | -8.4% | -7.6% | 3.4% |
| — | -109.4% | +42.3% | +43.4% | +46.1% | +940.1% | -63.4% | -38.4% | -432.8% | -31.2% | -6.4% | +0.0% | +148.2% | |
| ROA | -27.9% | -7.2% | -7.4% | -5.5% | -5.6% | 73.9% | -11.8% | -9.1% | -9.9% | -8.7% | -7.5% | -6.8% | 3.0% |
| — | -109.8% | +37.5% | +39.2% | +43.4% | +946.8% | -58.1% | -34.6% | -426.8% | -29.9% | -5.6% | +0.8% | +147.5% | |
| ROIC | -26.6% | -6.8% | -6.9% | -5.4% | -6.3% | -7.4% | -11.9% | -9.3% | -9.4% | -8.2% | -7.1% | -6.6% | -7.2% |
| — | +8.4% | +42.3% | +41.8% | +32.6% | +8.8% | -67.0% | -40.8% | -30.7% | -27.9% | -14.2% | -4.6% | -4.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 53.7% YoY to 13.82x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.10 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 |
| — | -7.3% | -63.6% | -60.7% | -58.3% | -56.1% | +19.5% | +15.7% | +14.1% | +0.5% | +0.9% | +1.4% | +3.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.46 | 13.82 | 14.48 | 18.50 | 11.90 | 8.99 | 10.09 | 12.84 | 12.27 | 12.06 | 13.73 | 17.55 | 13.30 |
| — | +53.7% | +43.5% | +44.1% | -3.0% | -25.4% | -26.5% | -26.8% | -7.7% | -17.7% | -23.6% | -17.6% | -25.3% | |
| Quick Ratio | 11.06 | 13.39 | 14.04 | 17.93 | 11.56 | 8.77 | 9.71 | 12.39 | 11.99 | 11.76 | 13.45 | 17.30 | 13.16 |
| — | +52.7% | +44.6% | +44.7% | -3.6% | -25.4% | -27.8% | -28.4% | -8.9% | -19.2% | -24.8% | -18.6% | -26.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAgios Pharmaceuticals, Inc.'s current P/E is -4.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Agios Pharmaceuticals, Inc.'s current operating margin is -873.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Agios Pharmaceuticals, Inc.'s business trajectory between earnings reports.